MSD, Astellas Keep Fingers Crossed For EU Fast-Track Status
The European Medicines Agency is this week considering applications from two companies seeking the coveted accelerated assessment review pathway for their new products.
You may also be interested in...
Will regulators in the EU follow their US counterparts in requiring more efficacy data for Daiichi Sankyo’s acute myeloid leukemia drug quizartinib, which is already approved in Japan?
The World Health Organization is laying down the ground work to ensure that African countries at risk of an Ebola outbreak are able to approve the vaccine for use soon after it is authorized in the EU or the US.
Accelerated assessment requests at the European Medicines Agency.